Cargando…

Effect of Acetazolamide on Postural Control in Patients with COPD Travelling to 3100 m Randomized Trial

Patients with chronic obstructive pulmonary disease (COPD) may be susceptible to impairments in postural control (PC) when exposed to hypoxia at high altitude. This randomized, placebo-controlled, double-blind, parallel-design trial evaluated the effect of preventive acetazolamide treatment on PC in...

Descripción completa

Detalles Bibliográficos
Autores principales: Buergin, Aline, Furian, Michael, Mayer, Laura, Lichtblau, Mona, Scheiwiller, Philipp M., Sheraliev, Ulan, Sooronbaev, Talant M., Ulrich, Silvia, Bloch, Konrad E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960941/
https://www.ncbi.nlm.nih.gov/pubmed/36835782
http://dx.doi.org/10.3390/jcm12041246
_version_ 1784895633200513024
author Buergin, Aline
Furian, Michael
Mayer, Laura
Lichtblau, Mona
Scheiwiller, Philipp M.
Sheraliev, Ulan
Sooronbaev, Talant M.
Ulrich, Silvia
Bloch, Konrad E.
author_facet Buergin, Aline
Furian, Michael
Mayer, Laura
Lichtblau, Mona
Scheiwiller, Philipp M.
Sheraliev, Ulan
Sooronbaev, Talant M.
Ulrich, Silvia
Bloch, Konrad E.
author_sort Buergin, Aline
collection PubMed
description Patients with chronic obstructive pulmonary disease (COPD) may be susceptible to impairments in postural control (PC) when exposed to hypoxia at high altitude. This randomized, placebo-controlled, double-blind, parallel-design trial evaluated the effect of preventive acetazolamide treatment on PC in lowlanders with COPD traveling to 3100 m. 127 lowlanders (85 men, 42 women) with moderate to severe COPD, aged 57 ± 8 y, living below 800 m, were randomized to treatment with acetazolamide 375 mg/d starting 24 h before ascent from 760 m to 3100 m and during a 2-day sojourn in a clinic at 3100 m. PC was evaluated at both altitudes with a balance platform on which patients were standing during five tests of 30 s each. The primary outcome was the center of pressure path length (COPL). In the placebo group, COPL significantly increased from (mean ± SD) 28.8 ± 9.7 cm at 760 m to 30.0 ± 10.0 cm at 3100 m (p = 0.002). In the acetazolamide group, COPL at 760 m and 3100 m were similar with 27.6 ± 9.6 cm and 28.4 ± 9.7 cm (p = 0.069). The mean between-groups difference (acetazolamide-placebo) in altitude-induced change of COPL was −0.54 cm (95%CI −1.66 to 0.58, p = 0.289). Multivariable regression analysis confirmed an increase in COPL of 0.98 cm (0.39 to 1.58, p = 0.001) with ascent from 760 to 3100 m, but no significant effect of acetazolamide (0.66 cm, 95%CI −0.25 to 1.57, p = 0.156) when adjusting for several confounders. In lowlanders with moderate to severe COPD, an ascent to high altitude was associated with impaired postural control and this was not prevented by acetazolamide.
format Online
Article
Text
id pubmed-9960941
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99609412023-02-26 Effect of Acetazolamide on Postural Control in Patients with COPD Travelling to 3100 m Randomized Trial Buergin, Aline Furian, Michael Mayer, Laura Lichtblau, Mona Scheiwiller, Philipp M. Sheraliev, Ulan Sooronbaev, Talant M. Ulrich, Silvia Bloch, Konrad E. J Clin Med Article Patients with chronic obstructive pulmonary disease (COPD) may be susceptible to impairments in postural control (PC) when exposed to hypoxia at high altitude. This randomized, placebo-controlled, double-blind, parallel-design trial evaluated the effect of preventive acetazolamide treatment on PC in lowlanders with COPD traveling to 3100 m. 127 lowlanders (85 men, 42 women) with moderate to severe COPD, aged 57 ± 8 y, living below 800 m, were randomized to treatment with acetazolamide 375 mg/d starting 24 h before ascent from 760 m to 3100 m and during a 2-day sojourn in a clinic at 3100 m. PC was evaluated at both altitudes with a balance platform on which patients were standing during five tests of 30 s each. The primary outcome was the center of pressure path length (COPL). In the placebo group, COPL significantly increased from (mean ± SD) 28.8 ± 9.7 cm at 760 m to 30.0 ± 10.0 cm at 3100 m (p = 0.002). In the acetazolamide group, COPL at 760 m and 3100 m were similar with 27.6 ± 9.6 cm and 28.4 ± 9.7 cm (p = 0.069). The mean between-groups difference (acetazolamide-placebo) in altitude-induced change of COPL was −0.54 cm (95%CI −1.66 to 0.58, p = 0.289). Multivariable regression analysis confirmed an increase in COPL of 0.98 cm (0.39 to 1.58, p = 0.001) with ascent from 760 to 3100 m, but no significant effect of acetazolamide (0.66 cm, 95%CI −0.25 to 1.57, p = 0.156) when adjusting for several confounders. In lowlanders with moderate to severe COPD, an ascent to high altitude was associated with impaired postural control and this was not prevented by acetazolamide. MDPI 2023-02-04 /pmc/articles/PMC9960941/ /pubmed/36835782 http://dx.doi.org/10.3390/jcm12041246 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Buergin, Aline
Furian, Michael
Mayer, Laura
Lichtblau, Mona
Scheiwiller, Philipp M.
Sheraliev, Ulan
Sooronbaev, Talant M.
Ulrich, Silvia
Bloch, Konrad E.
Effect of Acetazolamide on Postural Control in Patients with COPD Travelling to 3100 m Randomized Trial
title Effect of Acetazolamide on Postural Control in Patients with COPD Travelling to 3100 m Randomized Trial
title_full Effect of Acetazolamide on Postural Control in Patients with COPD Travelling to 3100 m Randomized Trial
title_fullStr Effect of Acetazolamide on Postural Control in Patients with COPD Travelling to 3100 m Randomized Trial
title_full_unstemmed Effect of Acetazolamide on Postural Control in Patients with COPD Travelling to 3100 m Randomized Trial
title_short Effect of Acetazolamide on Postural Control in Patients with COPD Travelling to 3100 m Randomized Trial
title_sort effect of acetazolamide on postural control in patients with copd travelling to 3100 m randomized trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9960941/
https://www.ncbi.nlm.nih.gov/pubmed/36835782
http://dx.doi.org/10.3390/jcm12041246
work_keys_str_mv AT buerginaline effectofacetazolamideonposturalcontrolinpatientswithcopdtravellingto3100mrandomizedtrial
AT furianmichael effectofacetazolamideonposturalcontrolinpatientswithcopdtravellingto3100mrandomizedtrial
AT mayerlaura effectofacetazolamideonposturalcontrolinpatientswithcopdtravellingto3100mrandomizedtrial
AT lichtblaumona effectofacetazolamideonposturalcontrolinpatientswithcopdtravellingto3100mrandomizedtrial
AT scheiwillerphilippm effectofacetazolamideonposturalcontrolinpatientswithcopdtravellingto3100mrandomizedtrial
AT sheralievulan effectofacetazolamideonposturalcontrolinpatientswithcopdtravellingto3100mrandomizedtrial
AT sooronbaevtalantm effectofacetazolamideonposturalcontrolinpatientswithcopdtravellingto3100mrandomizedtrial
AT ulrichsilvia effectofacetazolamideonposturalcontrolinpatientswithcopdtravellingto3100mrandomizedtrial
AT blochkonrade effectofacetazolamideonposturalcontrolinpatientswithcopdtravellingto3100mrandomizedtrial